China: China´s Competition Regulator Imposes Conditions On Two Proposed Mergers Under The AML

Last Updated: 12 October 2009
Article by Martyn Huckerby and Malcolm Leong

China's Ministry of Commerce (MOFCOM) has continued its recent trend of taking an activist approach to merger control in imposing conditions under the Anti-Monopoly Law (AML) on the clearance of two proposed mergers, Pfizer/Wyeth and General Motors/Delphi.

General Motors' Acquisition Of Delphi Subject To Conditions - 28 September 2009

On 28 September 2009, MOFCOM announced its decision to clear General Motors Company's (GM) acquisition of Delphi Corporation (Delphi). The clearance is subject to conditions placed on both GM and Delphi.

Background And Merger Review Process

GM is a US car manufacturer with a leading position in the global and Chinese car market. GM manufactures and sells passenger cars and commercial vehicles in China. Delphi is a US manufacturer of automotive components which was spun off from GM in 1999 and filed for bankruptcy in 2005. In China, Delphi is an exclusive supplier to a number of vehicle manufacturers.

The sale of Delphi to GM has been approved by US and EU courts and the transaction obtained clearance from the European Commission under the EU Merger Regulation on 13 August 2009.

GM submitted a merger filing to MOFCOM on 18 August 2009. MOFCOM commenced a preliminary review on 31 August 2009 and on 28 September 2009 it announced it had cleared the transaction, subject to conditions.

MOFCOM's Competition Concerns And Conditions Of Clearance

MOFCOM identified that although there is no horizontal overlap between the products and services provided by GM and those of Delphi, the parties do have a vertical relationship in the upstream and downstream automotive markets. Considering both parties are in a leading position in their respective relevant market in China, MOFCOM determined that the transaction could have an adverse impact on competition in both the Chinese vehicle market and the upstream automotive components market.

However, the parties to the transaction provided a remedy proposal which MOFCOM believes is sufficient to address its competition concerns and to alleviate any negative impact. MOFCOM therefore accepted the remedy proposal of the parties and granted approval subject to conditions. The table below illustrates the competition issues identified by MOFCOM and the relevant remedies imposed on GM and Delphi.

MOFCOM's Competition Concerns

Remedies Imposed By MOFCOM

As Delphi is the exclusive supplier to many Chinese vehicle manufacturers, the concentration may result in an adverse impact on the supply of components to Chinese vehicle manufacturers in terms of supply stability, price and quality, which would have the effect of eliminating or restricting competition in the Chinese car market.

After the concentration is completed, GM and Delphi must guarantee that Delphi and its controlling affiliates shall continue to supply products to Chinese vehicle manufacturers without any discrimination. The parties shall also undertake that Delphi and its controlling affiliates will guarantee a timely, reliable and quality delivery as usual, and will guarantee the price and quantity of supply to be determined by market rules or agreements. Further the supply must not be subject to any unreasonable conditions which may directly or indirectly eliminate or exclude market competition.

Considering GM's possible participation on Delphi's board of directors, GM may be able to obtain from Delphi sensitive information of other Chinese vehicle manufacturers, such as R&D technology and car model material, which would have the effect of eliminating or restricting competition in the Chinese car market.

After the concentration is completed:

  • GM must not illegally seek confidential information of other Chinese vehicle manufacturers from Delphi
  • Delphi must not illegally reveal to GM any confidential information of other Chinese vehicle manufacturers which is under its possession, and
  • Both parties must not formally or informally illegally exchange or communicate third parties' confidential information that is in relation to competition.

Where Chinese vehicle manufacturers intend to switch to other automotive components suppliers, Delphi may not be cooperative and thus may increase the cost of doing so. This will also have the effect of eliminating or restricting competition in the Chinese car market.

After the transaction is completed, GM and Delphi must guarantee that Delphi and its controlling affiliates will cooperate with clients in changing their suppliers upon each client's legitimate request. The parties must also guarantee that Delphi and its controlling affiliates would not deliberately delay clients changing or impose restrictive conditions in order to increase the cost for such change.

GM may increase its procurement of automotive components from Delphi after the concentration is completed, which may make it more difficult for other automotive components enterprises to access GM's procurement channel. This will have the effect of eliminating or restricting competition in the Chinese automotive components market.

After the concentration is completed, GM must continue to procure automotive components from various sources without any discrimination. GM shall not impose unreasonable conditions which are in favour of Delphi and unfavourable to other suppliers.

Pfizer's Acquisition Of Wyeth Subject To Conditions - 29 September 2009

On 29 September 2009, just one day after the GM/Delphi decision, MOFCOM announced another clearance, with restrictive conditions, for Pfizer Inc.'s (Pfizer) acquisition of Wyeth Corporation (Wyeth).

Background And Merger Review Process

Pfizer is a US pharmaceutical company with global operations in the human health and animal health sector, as is its rival, Wyeth. Both companies supply a number of human health and animal health products in China, including J1C (penbritin), N6A (anti-depressants), a vaccine for swine mycoplasma pneumonia, and a vaccine for swine pseudorabies and mixed vaccine for dogs.

MOFCOM received Pfizer's merger filing application regarding its proposed acquisition of Wyeth on 9 June 2009. MOFCOM commenced its preliminary review on 15 June. By 15 July, which was the expected deadline of the preliminary review, MOFCOM identified competition issues regarding the transaction in the area of animal health products and therefore decided to conduct a further review. Finally, on 29 September, MOFCOM announced it had cleared the concentration, subject to conditions.

The European Commission and the Commerce Commission of New Zealand gave approval to the deal in July and August 2009 respectively, while the Australian Competition and Consumer Commission cleared the transaction in September 2009 subject to an undertaking to divest certain assets. The transaction remains subject to regulatory approval in the US and Canada.

Competition Concerns

MOFCOM considered following its investigation that the concentration between Pfizer and Wyeth may have the effect of limiting or excluding competition in the market for swine mycoplasma pneumonia vaccine. According to the information obtained by MOFCOM:

  • The market share of the merged entity would reach 49.4% (Pfizer now holds 38% and Wyeth 11.4%) which is a much larger share than Intervet/Schering-Plough Animal Health, who is second in the market with only 18.35%, and other competitors in the market which hold less than 10% of the market. As such, the merged entity would have the ability to use its scale to expand in the market and to control the market price
  • Market concentration is high and as a result the proposed concentration would have the effect of eliminating or excluding competition in the Chinese market of swine mycoplasma pneumonia vaccine, as evidenced by analysis using the Herfindahl-Hirschman Index (HHI), and
  • Technological barriers to entry into the relevant market would be even higher and the merged entity might limit other companies from development by taking advantage of its scale in the Chinese market.

MOFCOM Decision And Conditions Of Clearance

MOFCOM consulted extensively with relevant government agencies, industry associations, competitors, upstream and downstream entities and also discussed proposed conditions with Pfizer to address its concerns.

MOFCOM imposed a series of conditions on clearance of the merger, whereby Pfizer must divest its swine mycoplasma pneumonia vaccine business in mainland China under its brands of "Respisure" and "Respisure One". The subject matter of the divestiture includes any tangible, intangible assets and intellectual property rights of Pfizer which are necessary to ensure the continuity and competitiveness of the divested business. Within six months, Pfizer must, through a trustee, find an independent buyer that is approved by MOFCOM and execute an agreement for sale of the relevant business. If Pfizer fails to find a buyer within the above prescribed period, MOFCOM may appoint a new trustee to dispose the relevant business with no set minimum price.

MOFCOM has also required that a provisional manager be appointed by Pfizer during the six months divestiture period. The manager is to monitor the divestiture and is to protect the continuity, marketable quality, competitiveness and independency of the business to be divested.

Further, for a period of three years following the divestiture, Pfizer is required, upon the request of the buyer, to provide reasonable technical support, to assist in purchasing materials needed for the production of the swine mycoplasma pneumonia vaccine, and to provide training and consultancy services to the buyer and its staff.

Implications

Both merger decisions highlight the activist role MOFCOM is starting to take, particularly as it seeks to foster a culture of compliance with the AML and position itself as one of the leading competition regulators in the region. It further highlights the importance of implementing a carefully planned Chinese merger control strategy where a transaction involves two or more firms with operations in the same or related market in China.

Both of MOFCOM's merger clearance decisions concern acquisitions by US companies where both parties have businesses in China with considerable market share. It may be seen from the decisions that:

  • For transactions where two or more parties have operations in the same or related markets in China MOFCOM will extensively consult with parties and carefully consider the feasibility of granting merger clearance subject to restrictive conditions as an alternative to outright refusal
  • MOFCOM is adopting internationally-accepted methods for carrying out its investigations, such as the use of the HHI index, and continuing its trend (as per its previous InBev/A-B and Mitsubishi Rayon/Lucite decisions) of considering remedies routinely used in other jurisdictions as a means of alleviating its concerns. An example of this is the use of trustees to effect the sale of the swine mycoplasma pneumonia vaccine business in mainland China by Pfizer
  • The behavioural remedies imposed in both cases are likely to require ongoing monitoring by MOFCOM (and the potential for MOFCOM to need to deal with third party complaints). This suggests that MOFCOM is not yet adopting the approach of other competition regulators in preferring remedies that do not require them to have an ongoing role in enforcement
  • Despite the willingness of MOFCOM to consider the use of behavioural remedies, MOFCOM will be prepared to require divesture as a remedy to alleviate any negative impact that might be caused by a transaction, and
  • Merger clearance by Chinese authorities continues to be an important aspect of international transactions, given the significant number of international businesses with a presence in Chinese markets. The complexity of the process and importance of third party comments suggest that where the merging parties are in the same or related sectors, there will be value in appointing both an external law firm and a public relations agency, which is a strategy frequently employed in other jurisdictions.

While most decisions of MOFCOM do not result in conditions or prohibition of the transaction (and therefore do not need to be reported), the latest two decisions are helpful in understanding the approach MOFCOM will take in less straightforward cases. Following these two "warning shots" merging parties will only ignore the Chinese merger control process at their peril.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions